ESMO 2024: Treatment of uHCC - Episode 13

Discussion of RESORCE Trial

November 22, 2024

Richard Finn, MD, Olatunji Alese, MD, Daneng Li, MD, Anthony El-Khoueiry, MD, Masatoshi Kudo, MD, PhD, Steven Chan, MD

Panelists discuss the data from the RESORCE trial, highlighting the efficacy of regorafenib in previously treated hepatocellular carcinoma, including primary trial results and insights on time to progression based on prior sorafenib treatment.

EP. 1: Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)

EP. 2: Treatment Decisions Based on BLCL Stage

EP. 3: Current Treatment in First Line – IO + TKI or IO + IO

EP. 4: Use of monotherapy (IO or TKI) or localized treatment in First Line

EP. 5: EMERALD-1 Study Results

EP. 6: Discussion and Summary

EP. 7: LEAP-012 Study Results

EP. 8: Discussion of LEAP-012 and EMERALD-1 Study Results and Appropriate Sequencing

EP. 9: ImBRAVE 050 Study Results and Discussion Around Who is a High-Risk Patient

EP. 10: Choosing Second-Line Therapies: Considering First Line Therapy Received

EP. 11: Discussion of CELESTIAL Trial and Second-Line Treatment in Japan

EP. 12: CELESTIAL Sub-Group Discussion

Now Viewing

EP. 13: Discussion of RESORCE Trial

EP. 14: Real-World Treatment Data from the Phase 4 STELLAR Trial

Video content above is prompted by the following:

Dr Li: Please discuss the data for regorafenib for previously treated hepatocellular carcinoma HCC from the RESORCE trial.
• Primary trial results – (Bruix J, et al. Lancet. 2017)
• Time to progression (TTP) based on TTP during sorafenib treatment – (Finn RS, et al. J Hepatol. 2018)